[Enterohemorrhagic Escherichia coli infection].
Nakayama
Kenji
K
Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Hospital.
Sato
Toshinobu
T
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004927:Escherichia coli Infections / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy*; D019453:Escherichia coli O157 / Q000472:pathogenicity; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D010951:Plasma Exchange; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D006435:Renal Dialysis; D022622:Shiga Toxin 1 / Q000096:biosynthesis / Q000633:toxicity; D022641:Shiga Toxin 2; D022603:Shiga Toxins / Q000096:biosynthesis / Q000633:toxicity
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D010975:Platelet Aggregation Inhibitors; D022622:Shiga Toxin 1; D022641:Shiga Toxin 2; D022603:Shiga Toxins; C430449:verocytotoxin 2